Dutch Belgian randomised lung cancer screening trial (NELSON).

No registrations found.

Ethical review	Positive opinion
Status	Other
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON22971

Source
NTR

Brief title
NELSON

Health condition

lung cancer

Sponsors and support

Primary sponsor: - KWF Kankerbestrijding
- ZONMW
Source(s) of monetary or material Support: - Stichting Centraal Fonds Reserves van Voormalig Vrijwillige Ziekenfondsverzekeringen (RvvZ)
- Siemens Germany
- G. Ph. Verhagen Stichting
- Rotterdam Oncologic Thoracic Steering committee (ROTS)
- Erasmus Trust fund
- Stichting tegen Kanker
- Vlaamse Liga tegen Kanker

Intervention

Outcome measures

Primary outcome

Lung cancer mortality (reduction).

Secondary outcome

1. Cost-effectiveness;

2. Quality of Life.

Study description

Background summary

Today, only 20% of lung cancers are at a resectable stage (stage I/II). 5-year survival is therefore low (15%). Computed Tomography (CT) screening detects more lung cancers than chest X-ray. It is unknown if this will translate into a lung cancer mortality reduction. The purpose of the NELSON trial is -to establish in a randomised controlled trial if screening for lung cancer by multi-slice low-dose CT in high risk subjects will lead to a 25% decrease in lung cancer mortality -to estimate the impact of lung cancer screening on health related quality of life and smoking cessation, and -to estimate cost-effectiveness and help policy making. Subjects with a high risk for lung cancer were first identified from the general population by sending a health questionnaire to approximately 500,000 men and women aged 50-74 in seven Dutch public health districts and 17 municipalities in Belgium. Eligible responders (n=30,134) were invited to participate. These were current smokers (55%) and former smokers (45%) who (had) smoked at least 16 cigarettes a day for at least 26 years or at least 11 cigarettes a day for at least 31 years. This was estimated to be the most optimal trial population. After giving informed consent (51.5%), 15,523 participants were randomised so far (1:1) to receive screening in year 1, 2 and 4 or usual care. The remaining 4,050 subjects needed to reach 80% power have been recruited in Denmark, and the Danish trial results will be uploaded at regular intervals to our database. CT screenings started in April 2004, performed with 16-detector multi-slice Spiral CT scanners and Siemens Lungcare® workstations and software for volumetric analyses. Both responders and trial participants appeared to be representative of the Dutch population of (heavy) current or former smokers. All baseline screenings and half of the second round screenings have at present been performed. At baseline screening, nodules have been categorised according to size and structure, at annual repeat screening according to the presence or absence of growth and according to volume doubling time (or being a new nodule). In the years 2007-2010 second and fourth year screens will be finalised. Lung cancer and all cause mortality in both study arms will be traced by linking our database to Statistics Netherlands and CBG. Causes of death of all lung cancer patients will be assessed by a review committee. Lung cancer cases, stages and tumor characteristics in both arms will be assessed by linkage to the regional

cancer registries to estimate lead time and sensitivity. In a large subcohort quality of life around screening, assessment and diagnosis will be assessed. At 1 and 3-year follow up, smoking patterns and attitudes will be assessed. All smokers receive general or tailored smoking cessation advice. Effects and costs will be estimated with a MISCAN model for lung cancer screening.

Study objective

1. To establish in a randomised controlled trial if screening for lung cancer by multi-slice low-dose CT in high risk subjects will lead to a 25% decrease in lung cancer mortality;

2. To estimate the impact of lung cancer screening on health related quality of life and smoking cessation;

3. To estimate cost-effectiveness and help policy making.

Intervention

1. Screen arm:

a. 16-detector multi-slice computed tomography of the chest in year 1, 2 and 4 of the study;

b. Pulmonory function test;

c. Blood sampling;

d. Questionnaires;

e. Smoking cessation advice for current smokers.

2. Control arm:

smoking cessation advice for current smokers;

3. A sample of controls:

a. Pulmonory function test;

b. Blood sampling;

c. Questionnaires.

Contacts

Public
Room AE-238, Erasmus MC
P.O. Box 2040
Harry J. Koning, de
Rotterdam 3000 CA
The Netherlands
+31 (0)10 7038460
Scientific
Room AE-238, Erasmus MC
P.O. Box 2040
Harry J. Koning, de
Rotterdam 3000 CA
The Netherlands
+31 (0)10 7038460

Eligibility criteria

Inclusion criteria

1. Born between 1928 and 1956;

2a. Smoked > 15 cigarettes/day during > 25 years or;

2b. Smoked > 10 cigarettes/day during > 30 years;

3. Current or former smokers who quit smoking =< 10 years ago.

Exclusion criteria

Subjects

1. With a moderate or bad self-reported health who were unable to climb two flights of stairs;

2. With a body weight >= 140 kilogram;

3. With current or past renal cancer, melanoma or breast cancer;

4. With lung cancer diagnosed less than 5 years ago or 5 years or more ago but still under treatment;

5. Who had a chest CT examination less than one year before they filled in the first NELSON questionnaire.

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active

Recruitment

NL
Recruitment status:	Other
Start date (anticipated):	16-08-2003
Enrollment:	15600
Type:	Unknown

Ethics review

Positive opinion
Date:	22-03-2006
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL580
NTR-old	NTR636
Other	: N/A
ISRCTN	ISRCTN63545820

Study results

Summary results
- van Klaveren RJ, de Koning HJ, Mulshine J, Hirsch FR. Lung cancer screening by spiral CT. What is the optimal target population for screening trials? Lung Cancer 2002;38:243-52.

- van Klaveren RJ, Hirsch FR, van Iersel CA, Bunn PA. The selection of the optimal target population for spiral CT screening and chemoprevention trials. In: Hirsch FR, Bunn PA, Kato H, Mulshine JL, editors. Textbook of Prevention and Detection of Early Lung Cancer. Abingdon, Oxon, UK: Taylor & Francis; 2006. p. 361-384.

- van Iersel CA, de Koning HJ, Draisma G, Mali WPTM, Scholten ETh, Nackaerts K, Prokop M, Habbema JDF, Oudkerk M, van Klaveren RJ. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2006; in press.